Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid plus bifidobacterium for chronic hepatitis B
ChiCTR2200062861Phase 4Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ursodeoxycholic acid and Golden Bifid in Chronic Hepatitis B (CHB) (3 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: HBV DNA quantitation, Liver function and 2 more. Started Apr 2022; status: completed.
02
Drugs
ursodeoxycholic acidGolden Bifid
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200062861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062861.